Cargando…

Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells

The microtubule-targeting agents (MTAs) are well-known chemotherapeutic agents commonly used for therapy of a broad spectrum of human malignancies, exhibiting epithelial origin, including breast, lung, and prostate cancer. Despite the impressive response rates shortly after initiation of MTA-based t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boichuk, Sergei, Dunaev, Pavel, Mustafin, Ilshat, Mani, Shinjit, Syuzov, Kirill, Valeeva, Elena, Bikinieva, Firuza, Galembikova, Aigul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945560/ https://www.ncbi.nlm.nih.gov/pubmed/35327403 http://dx.doi.org/10.3390/biomedicines10030601

Ejemplares similares

Establishment and Characterization of Multi-Drug Resistant p53-Negative Osteosarcoma SaOS-2 Subline
por: Boichuk, Sergei, et al.
Publicado: (2023)

Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors
por: Sergei, Boichuk, et al.
Publicado: (2020)

2-APCAs, the Novel Microtubule Targeting Agents Active against Distinct Cancer Cell Lines
por: Boichuk, Sergei, et al.
Publicado: (2021)

Inhibition of AKT-Signaling Sensitizes Soft Tissue Sarcomas (STS) and Gastrointestinal Stromal Tumors (GIST) to Doxorubicin via Targeting of Homology-Mediated DNA Repair
por: Boichuk, Sergei, et al.
Publicado: (2020)

The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site
por: Boichuk, Sergei, et al.
Publicado: (2021)

Computational-Based Discovery of the Anti-Cancer Activities of Pyrrole-Based Compounds Targeting the Colchicine-Binding Site of Tubulin
por: Boichuk, Sergei, et al.
Publicado: (2022)

BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression
por: Kim, Se Hyun, et al.
Publicado: (2018)

Inhibition of FGF2-Mediated Signaling in GIST—Promising Approach for Overcoming Resistance to Imatinib
por: Boichuk, Sergei, et al.
Publicado: (2020)

A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance
por: Boichuk, Sergei, et al.
Publicado: (2017)

Targeting of FGF-Signaling Re-Sensitizes Gastrointestinal Stromal Tumors (GIST) to Imatinib In Vitro and In Vivo
por: Boichuk, Sergei, et al.
Publicado: (2018)

Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
por: Boichuk, Sergei, et al.
Publicado: (2023)

Effects of FGFR inhibitors TKI258, BGJ398 and AZD4547 on breast cancer cells in 2D, 3D and tissue explant cultures
por: Kähkönen, T. E., et al.
Publicado: (2020)

Hematopoietic stem cell regulatory volumes as revealed in studies of the bgj/bgj:W/WV chimera
Publicado: (1978)

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
por: Lassman, Andrew B., et al.
Publicado: (2022)

Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma
por: Lyou, Yung, et al.
Publicado: (2022)

新酪氨酸激酶抑制剂BGJ398对白血病细胞株KG-1细胞的抑制效应研究
Publicado: (2018)

Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements
por: White, Kathryn, et al.
Publicado: (2023)

Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021)

Ribociclib enhances infigratinib‐induced cancer cell differentiation and delays resistance in FGFR‐driven hepatocellular carcinoma
por: Prawira, Aldo, et al.
Publicado: (2020)

FGF receptor inhibitor BGJ398 partially rescues osteoarthritis-like phenotype in older high molecular weight FGF2 transgenic mice via multiple mechanisms
por: Hurley, Marja M., et al.
Publicado: (2022)

Correction to: Infigratinib: First Approval
por: Kang, Connie
Publicado: (2021)

SUN-087 FGFR-Selective Tyrosine Kinase Inhibitors, Such as Infigratinib, Show Potency and Selectivity for FGFR3 at Pharmacologically Relevant Doses for the Potential Treatment of Achondroplasia
por: Dobscha, Katherine, et al.
Publicado: (2020)

SUN-101 Support for a New Therapeutic Approach of Using a Low-Dose FGFR Tyrosine Kinase Inhibitor (Infigratinib) for Achondroplasia
por: Demuynck, Benoit, et al.
Publicado: (2020)

Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma
por: Le, Thi Bich Uyen, et al.
Publicado: (2020)

Infigratinib in children with achondroplasia: the PROPEL and PROPEL 2 studies
por: Savarirayan, Ravi, et al.
Publicado: (2022)

Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()
por: Chilà, Rosaria, et al.
Publicado: (2017)

OR21-05 Low-dose Infigratinib, An Oral Selective Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, Demonstrates Activity In Murine Models Of Achondroplasia And Hypochondroplasia
por: Muslimova, Elena, et al.
Publicado: (2023)

Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib
por: Yu, James, et al.
Publicado: (2021)

Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma
por: Huynh, Hung, et al.
Publicado: (2019)

Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System
por: Zhao, Dehua, et al.
Publicado: (2023)

Radiosensitization by the Selective Pan-FGFR Inhibitor LY2874455
por: Darwis, Narisa Dewi Maulany, et al.
Publicado: (2022)

SUN-098 Low-Dose Infigratinib Treatment Does Not Lead to Changes in Phosphorous Preclinically in Mice
por: Reyes, Maribel, et al.
Publicado: (2020)

PSAT106 Infigratinib in Children with Achondroplasia: Design of the PROPEL, PROPEL2 and PROPEL OLE Studies
por: Muslimova, Elena, et al.
Publicado: (2022)

Structural insights into the potency and selectivity of covalent pan-FGFR inhibitors
por: Qu, Lingzhi, et al.
Publicado: (2022)

Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
por: Wu, Daichao, et al.
Publicado: (2016)

Rogaratinib: A potent and selective pan‐FGFR inhibitor with broad antitumor activity in FGFR‐overexpressing preclinical cancer models
por: Grünewald, Sylvia, et al.
Publicado: (2019)

Infigratinib Reduces Fibroblast Growth Factor 23 (FGF23) and Increases Blood Phosphate in Tumor‐Induced Osteomalacia
por: Hartley, Iris R., et al.
Publicado: (2022)

Semi-Automated Cell Panning for Efficient Isolation of FGFR3-Targeting Antibody
por: Min, Byeongkwi, et al.
Publicado: (2021)

THU181 Evaluation Of Bone Mineral Density In A Cohort Of Children With ACH Participating In The PROPEL 2 Study Of Infigratinib
por: Savarirayan, Ravi, et al.
Publicado: (2023)

Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
por: Hanes, Robert, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ntt83gi7bt455kl7oq1fatu3nb